After a number of positive referals, Sound Bioventures decided to hire Andulf Advokater with Anders Apell and Ulf Edebrink, as their legal representatives. Anders and Ulf where part of founding Andulf Advokater, back in 2004, and specializes in private equity, venture capital and real estate fund formation. Johan Kördel commented: “Others had told us that Anders and Ulf have superb and strategic legal minds – Boy can we underwrite that! We are so happy to have them on our side. Experienced and efficient – they cut to the chase”
Sound Bioventures Works with Andulf Advokater
VarmX raises €30 million Series B2 financing for IND approvaland preparations for pivotal trial
Leiden, The Netherlands, 25 May 2023 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round. The round was led by Sound Bioventures whilst the European Innovation Council (EIC) Fund ...
Combining instinct & freedom to support startups
Casper Breum says he can usually tell early on if a startup will be a good fit for investment. As a founding partner at Sound Bioventures, Breum is involved in reviewing the roughly six hundred investor pitches from biotech companies the firm evaluates each year. His predictive ability was honed throughout his career, which he […]
We are excited to welcome Arthex to our portfolio
ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) The ArthemiRTM trial, a Phase I-IIa study of ATX-01 in DM1, is expected to initiate in 2H2023 Round led by Columbus Venture Partners, with participation of European Innovation Council (EIC), Hadean Ventures, Sound ...
Breye Therapeutics Strengthens Management Team and Board
“We are thrilled to welcome Peter as CSO. His extensive experience in ophthalmology drug development will be invaluable as we advance our lead compound through clinical development. Gabriela’s appointment to the Board brings significant industry and development experience which will be instrumental as we build a pipeline of novel oral therapies for ...